• Axoltis Pharma

  Participated · Series A · Dec 2025

  Based in Clermont-Ferrand with offices in Lyon, Axoltis Pharma researches and develops innovative treatments for neurodegenerative and neurotraumatic diseases. Its lead asset, NX210c, is a 12-amino-acid cyclic peptide derived from SCO-Spondin that promotes blood–brain barrier restoration, offers neuroprotection, and enhances neurotransmission. The candidate holds orphan-drug designations from both the FDA and the EMA and demonstrated a favorable safety profile in a 2023 Phase 1b study. NX210c is now being evaluated in the Phase 2 SEALS trial in 82 ALS patients across 16 investigational centers, with results expected in Q2 2026. Proceeds from the latest capital raise will fund completion of this study and support exploratory work in additional neurological indications. The compound is protected by seven patents owned by Axoltis, and the company is actively pursuing a global pharmaceutical partnership, targeting discussions at the 2026 JP Morgan Healthcare Conference. While the company has not yet disclosed revenue, its financing underscores investor confidence in the differentiated technology and market potential.

• Rutile.bike

  Participated · Equity · Nov 2025

  Founded in 2021, Rutile.bike specializes in the reconditioning and resale of high-end electric bikes. The company operates a hybrid retail-repair outlet it calls a “Rutilerie,” blending showroom space with on-site maintenance services. Headquartered in Villeurbanne, Rutile.bike generated €2.20 million in revenue in 2024 and currently plans to expand its capacity to process 5,000 bikes annually by 2027. Near-term expansion includes opening a second Rutilerie in Ivry-sur-Seine and scaling to six such locations within two years. The startup also aims to deepen partnerships with original bike manufacturers to enhance product quality and after-sales service. Its focus on industrializing refurbishment processes underpins its growth strategy in the fast-growing circular mobility market.

• MagREEsource

  Participated · Equity · Sep 2025

  MagREEsource develops technology to manufacture permanent magnets from recycled rare-earth materials, offering magnets with a 91% lower carbon footprint compared with magnets from Chinese mining. The company operates a pilot plant in Noyarey that became operational in December 2024 and has a current capacity of 80 tonnes per year. It employs 50 people and uses two core processes that will form the basis of its future large-scale factory. MagREEsource plans a MagFactory targeted to reach 1,000 tonnes per year by 2028 and has been labeled a "Projet Stratégique Européen" under the EU Critical Raw Material Act. The startup aims to build a sovereign, low-carbon supply chain for magnets and to reduce dependence on the Chinese market. Target markets include wind power, aerospace, robotics and defense.

No current team members are available.